All Updates

All Updates

icon
Filter
Partnerships
Thermo Fisher Scientific, Mirxes, and National University Hospital collaborate for enhanced cancer genomic testing in Singapore
Precision Medicine
Jun 18, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Precision Medicine

Precision Medicine

Jun 18, 2024

Thermo Fisher Scientific, Mirxes, and National University Hospital collaborate for enhanced cancer genomic testing in Singapore

Partnerships

  • Thermo Fisher Scientific, the National University Hospital (NUH) Singapore, and Mirxes (a Singapore-based RNA technology company) have signed a Memorandum of Understanding (MOU) to collaborate on developing and clinically validating advanced genomic testing solutions tailored for the Southeast Asian population.

  • The partnership aims to increase access to affordable, advanced next-generation sequencing (NGS) genomic testing for cancer in Singapore and the region. It leverages Thermo Fisher's NGS systems, NUH's clinical expertise, and Mirxes' RNA technology to provide rapid and precise cancer diagnosis, enabling personalized treatment selection for optimized clinical outcomes.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.